Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 receptor agonists like semaglutide have transformed weight loss treatment, but pregnancy planning requires careful medical decisions. Current clinical evidence suggests stopping semaglutide at least two months before attempting conception is the safest approach, though individual timelines depend on your fertility goals and overall health status.
How Semaglutide Affects Fertility and Pregnancy Planning
Semaglutide is not approved for use during pregnancy, and animal studies have shown reproductive toxicity at high doses. The medication slows gastric emptying and reduces appetite through GLP-1 receptor activation, mechanisms that could theoretically affect nutrient absorption during critical fetal development windows. Most reproductive endocrinologists recommend discontinuing semaglutide at least 8–12 weeks before attempting conception to allow the body to clear the medication and reestablish normal metabolic function.
Weight loss itself may improve fertility outcomes in people with obesity-related infertility, particularly those with polycystic ovary syndrome (PCOS). However, rapid weight loss during the conception window can paradoxically reduce fertility due to hormonal disruption. Stopping semaglutide should be paired with a sustainable nutrition plan to maintain weight loss benefits while supporting ovulation and menstrual regularity.
Clinical Evidence on GLP-1 Use and Pregnancy Outcomes
The FDA Pregnancy Category for semaglutide is Category C, meaning animal reproduction studies have shown adverse effects but no adequate human pregnancy studies exist. Eli Lilly's tirzepatide carries similar classifications. No long-term human outcome data supports the safety of GLP-1 medications during pregnancy or while actively trying to conceive, making a washout period the standard of care recommended by fertility specialists.
A 2023 analysis in *Fertility and Sterility* noted that weight loss of 5–10% improves ovulatory function and pregnancy rates in women with obesity and infertility. The benefits of pre-conception weight management are real—but timing matters. Stopping GLP-1 therapy 2–3 months before conception attempts allows metabolic stabilization while preserving the weight loss achieved during treatment.
Personalized Fertility Planning with PlexusDx Precision Testing
PlexusDx Precision Peptide Genetic Test maps genetic variants in fertility-relevant pathways, including FTO rs9939609 and MC4R rs17782313, which influence metabolic response to weight loss and baseline fertility risk. Understanding your genetic predispositions to weight regain helps you and your fertility specialist design a conception timeline that maximizes the chances of sustained weight management post-treatment.
The test identifies how your body responds to semaglutide and other peptides before you start therapy, enabling personalized dosing and medication selection. For those planning conception, genetic insights can clarify whether alternative fertility-supportive interventions (like inositol supplementation or lifestyle modifications) should replace GLP-1 therapy during the conception window. PlexusDx Semaglutide Injection starts at $149/month, making pre-conception weight optimization accessible before you pause treatment for pregnancy planning.
Stopping Semaglutide: Timeline and Transition Strategy
If you are taking semaglutide and planning pregnancy, consult your prescribing physician and fertility specialist to establish a discontinuation plan. Most providers recommend tapering rather than abruptly stopping to minimize rebound weight gain and hormonal swings. A typical timeline involves stopping the medication 8–12 weeks before attempting conception, allowing two full menstrual cycles to pass after the last dose.
During the transition period, a registered dietitian can help you adopt maintenance eating patterns that preserve weight loss without GLP-1 support. This period is also ideal for optimizing micronutrient status (particularly folate, iron, and vitamin D), which directly impacts egg quality and early pregnancy health. Some patients benefit from reintroducing moderate exercise and stress-reduction practices to support ovulatory function as medication effects wear off.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to stay on semaglutide while trying to get pregnant?
No. Semaglutide is FDA Pregnancy Category C and should be discontinued at least 8–12 weeks before attempting conception. While weight loss before pregnancy improves fertility outcomes, the medication itself carries unknown reproductive risks, making a planned washout period essential.
How long does semaglutide stay in your system?
Semaglutide has a half-life of about 7 days, meaning it takes roughly 4–5 weeks to clear most of the medication from your body. However, fertility specialists recommend waiting 8–12 weeks total to allow full metabolic recovery and re-stabilization of hormonal cycles before attempting conception.
Can I use PlexusDx semaglutide before stopping for pregnancy?
Yes. PlexusDx compounded semaglutide injection starts at $149/month and can help you achieve significant weight loss before your planned conception timeline. Work with your fertility doctor to establish when to discontinue therapy, typically 2–3 months before you want to start trying.
What happens to weight loss after stopping semaglutide before conception?
Weight regain is common without structured nutrition support. During your discontinuation period, a dietitian can help you transition to sustainable eating patterns that maintain previous losses. Some patients experience 10–30% weight rebound within 6 months if lifestyle changes aren't reinforced.
How does the PlexusDx Precision Peptide Genetic Test support fertility planning?
The test analyzes variants like FTO rs9939609 and MC4R rs17782313 to reveal your genetic predisposition to weight regain and metabolic function. These insights help your fertility team predict whether you'll maintain weight loss naturally during conception attempts, or if additional support interventions are needed after semaglutide stops.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Treat Constipation from Zepbound: Effective Strategies and Solutions
Can You Start Zepbound at 7.5 mg? A Comprehensive Guide